Loading...
Please wait, while we are loading the content...
Similar Documents
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
| Content Provider | MDPI |
|---|---|
| Author | Yuan, Yu Adam, Abdalla Zhao, Chen Chen, Honglei |
| Copyright Year | 2021 |
| Description | Release of immunoreactive negative regulatory factors such as immune checkpoint limits antitumor responses. PD-L1 as a significant immunosuppressive factor has been involved in resistance to therapies such as chemotherapy and target therapy in various cancers. Via interacting with PD-1, PD-L1 can regulate other factors or lead to immune evasion of cancer cells. Besides, immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in the different tumors, but a significant percentage of patients cannot benefit from this therapy due to primary and acquired resistance during treatment. In this review, we described the utility of PD-L1 expression levels for predicting poor prognosis in some tumors and present evidence for a role of PD-L1 in resistance to therapies through PD-1/PD-L1 pathway and other correlating signaling pathways. Afterwards, we elaborate the key mechanisms underlying resistance to PD-1/PD-L1 blockade in cancer immunotherapy. Furthermore, promising combination of therapeutic strategies for patients resistant to PD-1/PD-L1 blockade therapy or other therapies associated with PD-L1 expression was also summarized. |
| Starting Page | 663 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers13040663 |
| Journal | Cancers |
| Issue Number | 4 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-02-07 |
| Access Restriction | Open |
| Subject Keyword | Cancers Oncology Pd-l1 Resistance Immune Checkpoints Immunotherapy |
| Content Type | Text |
| Resource Type | Article |
